Revolution Medicines, Inc., a prominent oncology company based in Redwood City, United States, has recently made headlines with its latest financial disclosures. As a Nasdaq-listed entity within the Health Care sector, the company is dedicated to discovering novel targeted therapies aimed at inhibiting elusive frontier targets within critical growth and survival pathways. This innovative approach seeks to revolutionize cancer treatment methodologies, serving a global customer base.
On May 28, 2026, Revolution Medicines filed a Form 4 with the Securities and Exchange Commission (SEC), detailing a series of transactions involving its common stock and stock options. The filing, submitted by Anthony Mancini, an officer of the company, outlines both the purchase and sale of shares. Mancini acquired a block of shares, increasing his holdings to approximately 57,000 shares. Concurrently, he sold several smaller blocks, resulting in a post-transaction total of about 54,000 shares.
Additionally, on the same day, 3,121 options were exercised at a conversion price of $33.62. This exercise converted into a larger block of shares, bringing Mancini’s overall ownership to approximately 106,000 shares. It is important to note that all these transactions were conducted under a 10b5-1 trading plan, which was adopted in December 2025. The filing also mentions that restricted stock units are included in the post-transaction holdings.
As of May 28, 2026, Revolution Medicines’ stock closed at $157.48, with a 52-week high of $158.13 and a low of $34 recorded on August 6, 2025. The company’s market capitalization stands at $32.53 billion. Despite its significant market presence, the company’s price-to-earnings ratio is currently at -21.57, reflecting its ongoing investment in research and development rather than immediate profitability.
Revolution Medicines continues to focus on its mission to transform cancer treatment through innovative therapies. For more information about their work and offerings, interested parties can visit their website at www.revmed.com .
